journal
MENU ▼
Read by QxMD icon Read
search

Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K

journal
https://www.readbyqxmd.com/read/30390009/creatine-kinase-pathway-inhibition-alters-gsk3-and-wnt-signaling-in-evi1-positive-aml
#1
Lina Benajiba, Gabriela Alexe, Angela Su, Emmanuel Raffoux, Jean Soulier, Michael T Hemann, Olivier Hermine, Raphael Itzykson, Kimberly Stegmaier, Alexandre Puissant
No abstract text is available yet for this article.
November 2, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30375490/cancer-from-the-perspective-of-stem-cells-and-misappropriated-tissue-regeneration-mechanisms
#2
Mariusz Z Ratajczak, Kamila Bujko, Aaron Mack, Magda Kucia, Janina Ratajczak
Tumorigenesis can be considered as pathologically misappropriated tissue regeneration. In this review we will address some unresolved issues that support this concept. First, we will address the issue of the identity of cancer-initiating cells and the presence of cancer stem cells in growing tumors. We will also ask are there rare and distinct populations of cancer stem cells in established tumor cell lines, or are all of the cells cancer stem cells? Second, the most important clinical problem with cancer is its metastasis, and here a challenging question arises: by employing radio-chemotherapy for tumor treatment, do we unintentionally create a prometastatic microenvironment in collateral organs? Specifically, many factors upregulated in response to radio-chemotherapy-induced injury may attract highly migratory cancer cells that survived initial treatment...
October 30, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30356161/targeted-killing-of-tnfr2-expressing-tumor-cells-and-t-regs-by-tnfr2-antagonistic-antibodies-in-advanced-s%C3%A3-zary-syndrome
#3
H Torrey, M Khodadoust, L Tran, D Baum, A Defusco, Y H Kim, D L Faustman
Sézary syndrome (SS) is a rare form of cutaneous T-cell lymphoma often refractory to treatment. SS is defined as adenopathy, erythroderma with high numbers of atypical T cells. This offers an opportunity for new interventions and perhaps antibody-based therapeutic by virtue of its high expression of the TNFR2 oncogene on the tumor cells and on T-regulatory cells (Tregs ). Potent human-directed TNFR2 antagonistic antibodies have been created that preferentially target the TNFR2 oncogene and tumor-infiltrating TNFR2+ Tregs ...
October 24, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30353031/il-2-and-il-15-blockade-by-bnz-1-an-inhibitor-of-selective-%C3%AE-chain-cytokines-decreases-leukemic-t-cell-viability
#4
T Tiffany Wang, Jun Yang, Yong Zhang, Meili Zhang, Sigrid Dubois, Kevin C Conlon, Yutaka Tagaya, Cait E Hamele, Shubha Dighe, Thomas L Olson, David J Feith, Nazli Azimi, Thomas A Waldmann, Thomas P Loughran
Interleukin-15 (IL-15) and IL-2 drive T-cell malignancies including T-cell large granular lymphocyte leukemia (T-LGLL) and HTLV-1 driven adult T-cell leukemia (ATL). Both cytokines share common γ-chain receptors and downstream signaling pathways. T-LGLL is characterized by clonal expansion of cytotoxic T cells and is associated with abnormal JAK/STAT signaling. ATL is an aggressive CD4+ T-cell neoplasm associated with HTLV-1. T-LGLL and ATL share dependence on IL-2 and IL-15 for survival and both diseases lack effective therapies...
October 23, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30353030/de-novo-gene-mutations-in-normal-human-memory-b-cells
#5
L M Slot, T A M Wormhoudt, M J Kwakkenbos, K Wagner, A Ballering, A Jongejan, A C M van Kampen, J E J Guikema, R J Bende, C J M van Noesel
In the past years, the genomes of thousands of tumors have been elucidated. To date however, our knowledge on somatic gene alterations in normal cells is very limited. In this study, we demonstrate that tetanus-specific human memory B lymphocytes carry a substantial number of somatic mutations in the coding regions of the genome. Interestingly, we observed a statistically significant correlation between the number of exome mutations and those present in the immunoglobulin heavy variable regions. Our findings indicate that the majority of these genomic mutations arise in an antigen-dependent fashion, most likely during clonal expansion in germinal centers...
October 23, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30353029/mitochondrial-apoptosis-is-induced-by-alkoxy-phenyl-1-propanone-derivatives-through-pp2a-mediated-dephosphorylation-of-bad-and-foxo3a-in-cll
#6
Mario Angelo Pagano, Elena Tibaldi, Pierfrancesco Molino, Federica Frezzato, Valentina Trimarco, Monica Facco, Giuseppe Zagotto, Giovanni Ribaudo, Luigi Leanza, Roberta Peruzzo, Ildikò Szabò, Andrea Visentin, Martina Frasson, Gianpietro Semenzato, Livio Trentin, Anna Maria Brunati
Protein phosphatase 2 A (PP2A) is a tumour suppressor whose strong inhibition underlies the phosphorylation-dependent, anti-apoptotic mechanisms in Chronic Lymphocytic Leukemia (CLL). Inactivation of PP2A is due to the cooperative action of the phosphorylation of Y307 of its catalytic subunit by the aberrant cytosolic pool of the Src Family Kinase Lyn and the interaction with its protein inhibitor SET, which is overexpressed in CLL. In this study, we developed a library of compounds, the most potent being the one named CC11, which restores PP2A activity by disrupting the PP2A/SET complex, thereby triggering the mitochondrial pathway of apoptosis...
October 23, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30341394/targeting-mek-in-vemurafenib-resistant-hairy-cell-leukemia
#7
Rebecca Caeser, Grace Collord, Wen-Qing Yao, Zi Chen, George S Vassiliou, Philip A Beer, Ming-Qing Du, Mike A Scott, George A Follows, Daniel J Hodson
No abstract text is available yet for this article.
October 19, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30323358/relapse-after-complete-response-in-newly-diagnosed-multiple-myeloma-implications-of-duration-of-response-and-patterns-of-relapse
#8
Surbhi Sidana, Nidhi Tandon, Angela Dispenzieri, Morie A Gertz, Francis K Buadi, Martha Q Lacy, David Dingli, Amie L Fonder, Suzanne R Hayman, Miriam A Hobbs, Wilson I Gonsalves, Rahma M Warsame, Taxiarchis Kourelis, Yi Lisa Hwa, Prashant Kapoor, Robert A Kyle, Nelson Leung, Ronald S Go, S Vincent Rajkumar, Shaji K Kumar
Achieving a complete response (CR) is associated with improved overall survival (OS) in multiple myeloma (MM), but data on duration of CR (DurCR) are limited. We evaluated 351 patients (2004-2016), achieving CR with first-line therapy. Patients with sustained DurCR ≥ 24 months (n = 177) had better OS; 150 vs. 81 months, p < 0.001. DurCR ≥ 24 months remained a significant predictor for OS (HR: 0.3, 95% CI: 0.2-0.5, p < 0.001) after adjusting for age, revised ISS stage, transplant and maintenance therapy...
October 15, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30323357/smc3-protein-levels-impact-on-karyotype-and-outcome-in-acute-myeloid-leukemia
#9
Bianca Kraft, Jan Lombard, Michael Kirsch, Patrick Wuchter, Peter Bugert, Thomas Hielscher, Norbert Blank, Alwin Krämer
No abstract text is available yet for this article.
October 15, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30315239/updated-results-from-the-phase-3-helios-study-of-ibrutinib-bendamustine-and-rituximab-in-relapsed-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma
#10
G Fraser, P Cramer, F Demirkan, R Santucci Silva, S Grosicki, A Pristupa, A Janssens, J Mayer, N L Bartlett, M-S Dilhuydy, H Pylypenko, J Loscertales, A Avigdor, S Rule, D Villa, O Samoilova, P Panagiotidis, A Goy, M A Pavlovsky, C Karlsson, M Hallek, M Mahler, M Salman, S Sun, C Phelps, S Balasubramanian, A Howes, A Chanan-Khan
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6 cycles of BR, followed by ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1-45.8). Investigator-assessed median progression-free survival (PFS) was not reached for ibrutinib+BR, versus 14...
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30315238/car-t-cells-for-t-cell-malignancies-challenges-in-distinguishing-between-therapeutic-normal-and-neoplastic-t-cells
#11
REVIEW
Marion Alcantara, Melania Tesio, Carl H June, Roch Houot
Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrated remarkable efficacy for the treatment of B-cell malignancies. The development of CAR T-cells against T-cell malignancies appears more challenging due to the similarities between the therapeutic, normal and malignant T-cells. The obstacles include CAR T-cell fratricide, T-cell aplasia, and contamination of CAR T-cell products with malignant T-cells. Here, we review these challenges and propose solutions to overcome these limitations.
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30315237/preclinical-assessment-of-an-antibody-pbd-conjugate-that-targets-bcma-on-multiple-myeloma-and-myeloma-progenitor-cells
#12
Krista Kinneer, Matt Flynn, Suneetha B Thomas, John Meekin, Reena Varkey, Xiaodong Xiao, Haihong Zhong, Shannon Breen, Paul G Hynes, Ryan Fleming, Binyam Bezabeh, Cui Tracy Chen, Leslie Wetzel, Ruoyan Chen, Nazzareno Dimasi, Yu-Tzu Tai, Kenneth C Anderson, Ronald Herbst, Philip W Howard, Elaine M Hurt, David A Tice
No abstract text is available yet for this article.
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30315236/determinants-of-long-term-outcome-in-type-1-calreticulin-mutated-myelofibrosis
#13
Natasha Szuber, Terra L Lasho, Christy Finke, Curtis A Hanson, Rhett P Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
No abstract text is available yet for this article.
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30315235/primary-systemic-amyloidosis-in-patients-with-waldenstr%C3%A3-m-macroglobulinemia
#14
Saurabh Zanwar, Jithma P Abeykoon, Stephen M Ansell, Morie A Gertz, Angela Dispenzieri, Eli Muchtar, Surbhi Sidana, Nidhi Tandon, S Vincent Rajkumar, David Dingli, Ronald Go, Martha Q Lacy, Taxiarchis Kourelis, Thomas E Witzig, David Inwards, Francis Buadi, Wilson Gonsalves, Thomas Habermann, Patrick Johnston, Grzegorz Nowakowski, Robert A Kyle, Shaji Kumar, Prashant Kapoor
No abstract text is available yet for this article.
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30315234/relative-survival-following-response-to-7-3-versus-azacytidine-is-similar-in-acute-myeloid-leukemia-and-high-risk-myelodysplastic-syndromes-an-analysis-of-four-swog-studies
#15
Megan Othus, Mikkael A Sekeres, Sucha Nand, Guillermo Garcia-Manero, Frederick R Appelbaum, Harry P Erba, Eli Estey
Here we quantify and compare the absolute and relative overall survival (OS) benefits conveyed by complete remission (CR) in AML and high-risk MDS, and by CR with incomplete count recovery (CRi) in AML and by hematologic improvement (HI) in MDS, following treatment with 7 + 3 versus azacytidine. We compared patients receiving 7 + 3 in SWOG studies S0106 (n = 301) and S1203 (n = 261) enrolling adults ≤ 60 years, with patients receiving azacytidine therapies in S0703 (n = 133 AML patients ≥ 60) and S1117 (n = 277 MDS patients ≥ 18)...
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30315233/second-cycle-remission-achievement-with-7-3-and-survival-in-adults-with-newly-diagnosed-acute-myeloid-leukemia-analysis-of-recent-swog-trials
#16
Megan Othus, Elihu H Estey, Guillermo Garcia-Manero, Brent L Wood, Derek L Stirewalt, John E Godwin, James K Weick, Jeanne E Anderson, Frederick R Appelbaum, Harry P Erba, Roland B Walter
No abstract text is available yet for this article.
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30315232/long-term-treatment-free-remission-of-chronic-myeloid-leukemia-with-falling-levels-of-residual-leukemic-cells
#17
David M Ross, Ilaria S Pagani, Naranie Shanmuganathan, Chung H Kok, John F Seymour, Anthony K Mills, Robin J Filshie, Christopher K Arthur, Phuong Dang, Verity A Saunders, Jodi Braley, Agnes S Yong, David T Yeung, Deborah L White, Andrew P Grigg, Anthony P Schwarer, Susan Branford, Timothy P Hughes
Following the achievement of deep molecular response on tyrosine kinase inhibitors (TKIs), approximately half of patients with chronic myeloid leukemia (CML) can discontinue TKI and remain in treatment-free remission (TFR). The ALLG CML8 study enrolled 40 imatinib-treated patients with undetectable BCR-ABL1 mRNA (approximately MR4.5 ). Molecular relapse was defined as detectable BCR-ABL1 on two consecutive tests or any single value >0.1%. With a median follow-up of 8.6 years (range 5.7-11.2 years), 18 patients remain in continuous TFR (45...
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30315231/activation-of-nf-%C3%AE%C2%BAb-driven-inflammatory-programs-in-mesenchymal-elements-attenuates-hematopoiesis-in-low-risk-myelodysplastic-syndromes
#18
Zhen Ping, Si Chen, Sjoerd J F Hermans, Keane J G Kenswil, Jacqueline Feyen, Claire van Dijk, Eric M J Bindels, Athina M Mylona, Niken M Adisty, Remco M Hoogenboezem, Mathijs A Sanders, Eline M P Cremers, Dicky J Lindenbergh-Kortleve, Janneke N Samsom, Arjan A van de Loosdrecht, Marc H G P Raaijmakers
No abstract text is available yet for this article.
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30315230/dux4-hd2-dna-erg-structure-reveals-new-insight-into-dux4-responsive-element
#19
Xue Dong, Hao Zhang, Nuo Cheng, Kening Li, Guoyu Meng
No abstract text is available yet for this article.
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30315229/inhibitors-of-the-protein-disulfide-isomerase-family-for-the-treatment-of-multiple-myeloma
#20
Reeder M Robinson, Leticia Reyes, Ravyn M Duncan, Haiyan Bian, Allen B Reitz, Yefim Manevich, Jesse J McClure, Matthew M Champion, C James Chou, Meahgen E Sharik, Marta Chesi, P Leif Bergsagel, Nathan G Dolloff
Multiple Myeloma (MM) is highly sensitive to disruptions in cellular protein homeostasis. Proteasome inhibitors (PIs) are initially effective in the treatment of MM, although cures are not achievable and the emergence of resistance limits the durability of responses. New therapies are needed for refractory patients, and those that combat resistance to standard of care agents would be particularly valuable. Screening of multiple chemical libraries for PI re-sensitizing compounds identified E61 as a potent enhancer of multiple PIs and MM specific activity...
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
journal
journal
20191
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"